Top

Published in:

Open Access 01-12-2007 | Gastrointestinal Oncology

Population-Based Study of Islet Cell Carcinoma

Authors: James C. Yao, MD, Milton P. Eisner, PhD, Colleen Leary, MPH, Cecile Dagohoy, MD, Alexandria Phan, MD, Asif Rashid, MD, Manal Hassan, MD, PhD, MPH, Douglas B. Evans, MD

Published in: Annals of Surgical Oncology | Issue 12/2007

Abstract

Background

We examine the epidemiology, natural history, and prognostic factors that affect the duration of survival for islet cell carcinoma by using population-based registries.

Methods

The Surveillance, Epidemiology, and End Results (SEER) Program database (1973–2003 release, April 2006) was used to identify cases of islet cell carcinoma by histology codes and tumor site.

Results

A total of 1310 (619 women and 691 men) cases with a median age of 59 years were identified. The annual age-adjusted incidence in the periods covered by SEER 9 (1973–1991), SEER 13 (1992–1999), and SEER 17 (2000–2003) were .16, .14, and .12 per 100,000, respectively. The estimated 28-year limited duration prevalence on January 1, 2003, in the United States was 2705 cases. Classified by SEER stage, localized, regional, and distant stages corresponded to 14%, 23%, and 54% of cases. The median survival was 38 months. By stage, median survival for patients with localized, regional, and distant disease were 124 (95% CI, 80–168) months, 70 (95% CI, 54–86) months, and 23 (95% CI, 20–26) months, respectively. By multivariate Cox proportional modeling, stage (P < .001), primary tumor location (P = .04), and age at diagnosis (P < .001) were found to be significant predictors of survival.

Conclusions

Islet cell carcinomas account for approximately 1.3% of cancers arising in the pancreas. Most patients have advanced disease at the time of diagnosis. Despite the disease’s reputation of being indolent, survival of patients with advanced disease remains only 2 years. Development of novel therapeutic approaches is needed.

Lamberts S, Uitterlinden P, Verschoor L, van Dongen K, del Pozo E. Long term treatment of acromegaly with the somatosatin analogue SMS201-995. N Engl J Med 1985;313:1576–80PubMedCrossRef

Debelenko LV, Brambilla E, Agarwal SK, et al. Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet 1997;6:2285–90PubMedCrossRef

Plank TL, Logginidou H, Klein-Szanto A, Henske EP. The expression of hamartin, the product of the TSC1 gene, in normal human tissues and in TSC1- and TSC2-linked angiomyolipomas. Mod Pathol 1999;12:539–45PubMed

Verhoef S, van Diemen-Steenvoorde R, Akkersdijk WL, et al. Malignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhood. Eur J Pediatr 1999;158:284–7PubMedCrossRef

Tan CC, Hall RI, Semeraro D, Irons RP, Freeman JG. Ampullary somatostatinoma associated with von Recklinghausen’s neurofibromatosis presenting as obstructive jaundice. Eur J Surg Oncol 1996;22:298–301PubMedCrossRef

Yoshida A, Hatanaka S, Ohi Y, Umekita Y, Yoshida H. von Recklinghausen’s disease associated with somatostatin-rich duodenal carcinoid (somatostatinoma), medullary thyroid carcinoma and diffuse adrenal medullary hyperplasia. Acta Pathol Jpn 1991;41:847–56PubMed

Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A 2005;102:8573–8PubMedCrossRef

Hammel PR, Vilgrain V, Terris B, et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d’Etude de la Maladie de von Hippel-Lindau. Gastroenterology 2000;119:1087–95PubMedCrossRef

Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934–59PubMedCrossRef

10.

Lepage C, Rachet B, Coleman MP. Survival from malignant digestive endocrine tumors in England and wales: a population-based study. Gastroenterology 2007;132:899–904PubMedCrossRef

11.

Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: SEER 17 Regs Nov 2005 sub (1973–2003), ed. released April 2006. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistic Branch, 2006. Available at: Available at: http://www.seer.cancer.gov. Accessed August 14, 2007

12.

Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449:395–401PubMedCrossRef

13.

Surveillance Research Program NCI. SEER*Stat software, version 6.2.4, 2006. Available at: http://www.seer.cancer.gov/seerstat/. Accessed August 14, 2007

14.

SEER Cancer Statistics Review, 1975–2003. Bethesda, MD: National Cancer Institute, 2006

15.

Byrne J, Kessler LG, Devesa SS. The prevalence of cancer among adults in the United States: 1987. Cancer 1992;69:2154–9PubMedCrossRef

16.

Solorzano CC, Lee JE, Pisters PW, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 2001;130:1078–85PubMedCrossRef

17.

Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;22:4762–71PubMedCrossRef

18.

Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519–23PubMedCrossRef

19.

Kouvaraki MA, Solorzano CC, Shapiro SE, et al. Surgical treatment of non-functioning pancreatic islet cell tumors. J Surg Oncol 2005;89:170–85PubMedCrossRef

20.

Eriksson B, Skogseid B, Lundqvist G, Wide L, Wilander E, Oberg K. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 1990;65:1883–90PubMedCrossRef

Title: Population-Based Study of Islet Cell Carcinoma
Authors: James C. Yao, MD
Milton P. Eisner, PhD
Colleen Leary, MPH
Cecile Dagohoy, MD
Alexandria Phan, MD
Asif Rashid, MD
Manal Hassan, MD, PhD, MPH
Douglas B. Evans, MD
Publication date: 01-12-2007
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 12/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-007-9566-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Population-Based Study of Islet Cell Carcinoma

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2007

Primary Tumor Resection in Stage IV Breast Cancer: Consistent Benefit, or Consistent Bias?

Can We Understand the Clinical Biology of Gastric Cancer and Exploit it? May be, but It is a Challenge!

Preoperative Portal Vein Embolization and Surgical Resection in Patients with Hepatocellular Carcinoma and Small Future Liver Remnant Volume: Comparison with Transarterial Chemoembolization

Intrahepatic Lymphatic Invasion Independently Predicts Poor Survival and recurrences after Hepatectomy in Patients with Colorectal Carcinoma Liver Metastases

Impact of Adjuvant Radiation on Survival: A Note of Caution When Using Cancer Registry Data to Evaluate Adjuvant Treatments

Minimally Invasive Radio-guided Surgery for Primary Hyperparathyroidism